Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Epidemiology and transmission dynamics of Trichomonas vaginalis infection among Iranian women: A framework for targeted public health interventions.Parasitology research · 2026Pooled it
- Vaginal Ecosystem During Gestation and Puerperium: Microbiota, Dysbiosis, Infection and Fetal-Maternal Implications.Microorganisms · 2026Review
- Trends in prevalence ofSexually transmitted infections · 2026Article
- A retrospective analysis of the correlation between vaginal microecology and high-risk HPV infection among 5727 women.BMC infectious diseases · 2026Article
- RefiningBMJ open · 2026Article
- Knowledge, Attitudes, and Practices Among Sexually Active Individuals Toward Trichomoniasis in the Ashaiman Municipality, Ghana: A Cross-Sectional Study.Health science reports · 2026Article
- Clinical and Molecular Diagnostic Profiling of Vaginitis Using Multiplex Real-Time PCR: A Multicenter Study.Diagnostics (Basel, Switzerland) · 2026Article
- The Role of the Vaginal Microbiome in Gynecological Diseases: Mechanistic Insights and Emerging Interventions.Biology · 2026Review
- Vaginal Microbiota Dysbiosis and Infections: A Comprehensive Review of Microbial and Therapeutic Perspectives.International journal of women's health · 2026Review
- From microscopy to molecular diagnostics: identifying the complexities of clinical diagnostics for vaginal infections.Microbiology spectrum · 2025Article
- New Trends in Sexually Transmitted Infections Among Adolescents and Young People: Epidemiology, Clinical and Diagnostic Management.Microorganisms · 2025Review
- Trichomonas vaginalis extracellular vesicles activate the NLRP3 inflammasome and TLR3-mediated inflammatory cascades in host cells.PLoS pathogens · 2025Article
- Trichomoniasis and Other Sexually Transmitted Parasitic Diseases in Women.Clinical obstetrics and gynecology · 2025Review
- Biomolecular Characterization ofBiology · 2025Article
- Forensic Microbiology: Challenges in Detecting Sexually Transmitted Infections.Diagnostics (Basel, Switzerland) · 2025Review
- Persistent trichomoniasis in a man in his early 90s with a history of prostatic hyperplasia: A case report.The Journal of international medical research · 2025Article
- Rising global burden of common gynecological diseases in women of childbearing age from 1990 to 2021: an update from the Global Burden of Disease Study 2021.Reproductive health · 2025Article
- Microbiome-Maternal Tract Interactions in Women with Recurrent Implantation Failure.Microorganisms · 2025Review
- The prevalence trends of Trichomonas vaginalis infection among women in Jingzhou, central of China, 2019-2023.BMC infectious diseases · 2025Article
- Unveiling shifts in cervical microbiota composition among Colombian women in the presence of Trichomonas vaginalis: a longitudinal study.Parasitology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
Abstract
Trichomonas vaginalis is likely the most prevalent nonviral sexually transmitted infection, affecting an estimated 3.7 million women and men in the United States. Health disparities are prominent in the epidemiology of trichomoniasis, as African Americans are >4 times more likely to be infected than persons of other races. Since publication of the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines, additional data have bolstered the importance of T. vaginalis infection sequelae in women, including increased risk of human immunodeficiency virus (HIV) acquisition, cervical cancer, preterm birth, and other adverse pregnancy outcomes. Less is known about the clinical significance of infection in men. Newly available diagnostic methods, including point-of-care assays and multiple nucleic acid amplification tests, can be performed on a variety of genital specimens in women and men, including urine, allowing more accurate and convenient testing and screening of those at risk for infection. Repeat and persistent infections are common in women; thus, rescreening at 3 months after treatment is recommended. In vitro antibiotic resistance to 5-nitroimidazole in T. vaginalis remains low (4.3%) but should be monitored. High rates of T. vaginalis among sexual partners of infected persons suggest a role for expedited partner treatment. A randomized controlled trial in HIV-uninfected women demonstrated that multidose metronidazole 500 mg twice daily for 7 days reduced the proportion of women with Trichomonas infection at 1 month test of cure compared with women receiving single-dose therapy (2 g). The 2-g single-dose oral metronidazole regimen remains the preferred treatment in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.